NitroMed (NTMD) Announces Merger Agreement with Deerfield Management
More News related to NTMD
- NitroMed (NTMD) Announces Merger Agreement with Deerfield Management
- NitroMed (NTMD) Agrees to be Acquired by Deerfield Management for $0.80/Share
- Deerfield Management Increases Its Offer For NitroMed (NTMD)
- NitroMed (NTMD) Confirms Receipt of Letter from Deerfield Management
- Notable Mergers and Acquisitions of the Day 12/05: MER/BAC, NTMD, RSG/AW
NitroMed, Inc. (NASDAQ: NTMD) announced that it entered into a merger agreement to be acquired by affiliates of Deerfield Management, a leading healthcare investment organization. Under the terms of the merger agreement with Deerfield, NitroMed stockholders will receive $.80 per share in cash, subject to adjustment for net cash balances at the closing of the merger.
Prior to entering into the merger agreement with Deerfield, NitroMed terminated its previously announced purchase and sale agreement with JHP Pharmaceuticals, LLC and its previously announced merger agreement with Archemix Corp. in accordance with the terms of those agreements, including the payment of termination fees. In connection with the termination of the JHP purchase and sale agreement, NitroMed paid a fee of approximately $900,000 to JHP; and in connection with the termination of the Archemix merger agreement, NitroMed paid a $1.5 million fee to Archemix.
NitroMed of Lexington, Massachusetts is the maker of BiDil (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients.[SM]
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
